65,437 trials
Diabetes Mellitus, Type 1
Primary: Safety and Tolerability as Measured by Adverse Events, Local Tolerability of Infusion Site Reactions, and Clinical Laboratory Parameters — 8; 12; 0; 0 Participants
Adenoid Hypertrophy
Primary: Average Pain Score — 0 pain score
Diabetes Mellitus, Type 2 · Coronary Artery Disease
Primary: P2Y12 Reaction Units (PRU) — 60; 146 PRU — p=0.001
Diabetes Mellitus
Primary: Change in A1c — -0.74 percent of hemoglobin
Hepatitis B · Vertical Transmission of Infectious Disease
Primary: Number of Participants With Lab Testing Acceptability Survey Scores >80% — 7; 41; 7; 40 Participants
Healthy
Primary: Standard Deviation of Lateral Position (SDLP) — 33.2; 34.2; 35.4; 47.4 centimeter (cm) — p=<0.001
X-linked Hypophosphatemia
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose…
HIV-1 Infection
Primary: Percentage of Participants With Successful Virological Suppression at Weeks 48 and 96 — 99.4; 98.7 percentage of participant
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Polyarticular Juvenile Rheumatoid Arthritis · Arthritis, Juvenile Idiopathic
Primary: Percentage of Participants With Clinically Inactive Disease (CID) Off Glucocorticoids — 32.3; 37.2; 24.2 percentage of participants achieving CID — p=>0.05
Post-fire Rehabilitation of Firefighters in Sauna
Primary: Urinary Excretion of Hydroxylated PAHs (PAH-OHs) — 10364.2; 40012.1; 6964.1; 22604.3 ng/L — p=0.0000009
Elite Athlete · Healthy
Primary: Maximal Fall in Forced Expiratory Volume in One-second (FEV1) After Eucapnic Voluntary Hyperventilation (EVH) Test — -4; -9; -9; -5 percentage of change in FEV1 after…
Liver Disease
Primary: Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) — 0.104; 0.092; 0.099 min-1
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Period Baseline at Week 2 in Constant Work Rate (CWR) Endurance Time Relative to Placebo — -1.4; -13.4 seconds — p=0.734
Neuromuscular Blockade
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to Infinity (AUC0-∞) of Sugammadex [Part A] — 14.1; 18.8; 27.6; 26.9 hr*μg/mL